Scienture Holdings, INC

Scienture Holdings, Inc. announced the resignation of CFO Eric Sherb and the appointment of Co-CEO Dr. Narasimhan Mani as Interim CFO.

Scienture Holdings reported a 449% year-over-year revenue increase to $56,000 and secured $11 million in non-dilutive debt financing.

Scienture Holdings, Inc. has posted a revised investor presentation to its website, containing forward-looking statements about projects, financial performance, and growth opportunities.

Scienture Holdings, Inc. has entered into a $11 million secured note purchase agreement with Streeterville Capital, LLC to fund working capital and product development.

Scienture Holdings, Inc. filed an 8-K announcing the posting of a revised investor presentation to its website and plans for investor meetings.

Scienture Holdings, Inc. stockholders approved director elections, an equity plan increase, a potential future stock offering, and a reverse stock split, but rejected a significant increase in authorized shares.

Scienture Holdings, Inc. reported increased revenues from its new pharmaceutical product SCN-102 but continued to post significant net losses and faces substantial doubt about its ability to continue as a going concern.

Scienture Holdings, Inc. reports a substantial net loss and critical cash shortage, raising going concern doubts despite a strategic pivot to specialty pharmaceuticals and a recent FDA approval.

Scienture Holdings, formerly TRxADE Health, announces its Q1 2025 financial results amidst strategic divestitures and a focus on branded pharmaceutical development.

Scienture Holdings, formerly TRxADE Health, reported its Q3 2024 results, highlighting a period of significant strategic changes including acquisitions, divestitures, and a name change.

TRxADE HEALTH, INC. reports a net income of $19.4 million for the six months ended June 30, 2024, primarily driven by gains from discontinued operations, while facing challenges in its continuing operations.

TRxADE HEALTH, INC. reports a net income of $21.2 million for Q1 2024, driven by strategic divestitures, despite a loss from continuing operations.

Scienture Holdings files an amended 2025 annual report to correct immaterial errors and provide required governance disclosures.

Scienture Holdings reported a $41.5M FY25 loss amid $26.3M impairments, launched FDA‑approved ARBLI and secured U.S. rights to 10mg naloxone nasal spray REZENOPY.

Scienture Holdings, formerly TRxADE HEALTH, reports its FY24 results, emphasizing the acquisition of Scienture LLC and a strategic shift towards CNS and CVS disease treatments.

TRxADE HEALTH, INC. has filed an amendment to its 2023 annual report on Form 10-K/A to include previously omitted information and updated certifications.

TRxADE HEALTH, INC. reports a net loss of $13.7 million for 2023, impacted by strategic divestitures and operational changes.

Scienture Holdings Co-CEO Shankar Hariharan reported significant changes in his beneficial ownership, including preferred stock conversions and restricted stock awards.

Narasimhan Mani, President & Co-CEO of Scienture Holdings, Inc., reported multiple transactions including conversion of preferred stock and awards of restricted common stock.

Surendra Ajjarapu, CEO of TRxADE HEALTH, files an amended SEC Form 4 to correct previously reported information regarding securities acquired, beneficial ownership, and form of ownership.

Prashant Patel, Interim CFO and Director of TRxADE HEALTH, files an amended Form 4 to correct details regarding a stock grant and beneficial ownership.

Scienture Holdings, Inc. is seeking shareholder approval for critical proposals including a reverse stock split to maintain Nasdaq listing, a significant increase in authorized shares, and a potential future capital raise of up to $500 million.

Scienture Holdings issues a proxy supplement to correct errors in the original notice and proxy statement, clarifying that the upcoming meeting on March 10, 2025, is the 2024 annual meeting.

Scienture Holdings has announced its 2025 annual meeting of stockholders to be held virtually on March 10, 2025, with several key proposals up for vote.

Scienture Holdings' stockholders have approved the issuance of common stock exceeding 20% of outstanding shares to Arena Investors and Arena Global, complying with Nasdaq Listing Rule 5635(d).

TRxADE Health, Inc. will change its name to Scienture Holdings, Inc. after completing its merger with Scienture, Inc., a specialty pharmaceutical company.

Scienture Holdings is registering for resale up to 2,643,421 shares of its common stock by selling stockholders after issuing secured convertible debentures.

Scienture Holdings is registering the resale of up to 4.3 million shares of common stock by selling stockholders, aiming to raise up to $50 million through an ELOC Purchase Agreement.

Scienture Holdings has filed an amendment to its S-1 registration statement to allow for the resale of up to 4.3 million shares of common stock by certain selling stockholders.

Scienture Holdings is registering the resale of up to 4.3 million shares of common stock by selling stockholders, including shares related to ELOC and Securities Purchase Agreements.

Scienture Holdings, Inc. has filed a registration statement for the resale of up to 4.3 million shares of its common stock by certain selling stockholders, primarily related to recent financing agreements.

L1 Capital Global Opportunities Master Fund, Ltd. has reported a complete divestment of its 1,075,000 shares in Scienture Holdings, Inc., reducing its beneficial ownership to zero.

Scoggin International Fund Ltd. and related entities have disclosed a passive 0.01% beneficial ownership stake in Scienture Holdings Inc., totaling 150,000 common shares.

L1 Capital Global Opportunities Master Fund, Ltd. has disclosed a passive 5.55% beneficial ownership stake in Scienture Holdings, Inc.